Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients USA – English 
Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that China’s National Medical Products Administration (NMPA) has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN)…
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announces the publication of preclinical research in Science Advances, highlighting the potential of its Tie2-activating antibody program, PMC-403, in treating Idiopathic Systemic Capillary Leak…
Women-led health and biotech companies dominate FACIT’s latest investments
On the globally-recognized Women’s Entrepreneurship Day, FACIT is pleased to announce investments in four breakthrough oncology innovations – all driven by women leaders. November 19th each year is a day to celebrate and showcase women’s contributions to advance communities and to strengthen…
Observe Oral Cancer Action Month with a complimentary oral cancer screening with your checkup at Babylon Dental Care
November is Oral Cancer Action Month, and Babylon Dental Care wants to emphasize the importance of early detection to treat these diseases effectively. We are committed to the health and well-being of our patients, which is why we always provide…
FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus
Today, the U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus. The chikungunya virus is primarily transmitted to…
March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma
March Biosciences (March Bio), a clinical stage biotechnology company committed to combating challenging cancers unresponsive to existing immunotherapies, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) to provide…
Monteris Medical Announces Extended Aetna® Coverage of its NeuroBlate® System Laser Interstitial Thermal Therapy for Brain Tumor Patients
Monteris Medical, the leader in minimally invasive image-guided laser interstitial thermal therapy (LITT), announced today that health insurance provider Aetna has updated its medical policy and will provide coverage to its beneficiaries with recurrent brain metastases, radiation necrosis and recurrent…
New York Festivals 2024 Health Awards Open for Entries
The New York Festivals 2024 NYF Health Awards, celebrating excellence in Healthcare, Wellness and Pharmaceutical advertising, is now open for entries. For 2024, New York Festivals Health Awards will once again hold live, face-to-face Executive Jury sessions in New York City with two separate Executive Juries…
Clarity and PSI kick off SAR-bisPSMA Phase III
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG (“PSI”), a global contract research organisation committed to on-time enrollment…
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the “Annual Meeting”),…
